Joshua P Klopper

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. ncbi Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, USA
    Mol Cancer 8:16. 2009
  2. ncbi Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment
    Joshua P Klopper
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Box B151, 4200 East 9th Avenue, Denver, CO 80262, USA
    Mol Cancer Ther 3:1011-20. 2004
  3. ncbi In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:589-96. 2008
  4. ncbi Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
    Jena D French
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 97:E934-43. 2012
  5. ncbi Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids
    Bryan R Haugen
    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Clin Endocrinol Metab 89:272-80. 2004
  6. ncbi Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult
    David Howard
    Department of Medicine, Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 96:1966-70. 2011
  7. ncbi Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification
    Rebecca E Schweppe
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 93:4331-41. 2008
  8. ncbi Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer
    Jena D French
    Department of Medicine, University of Colorado Denver, 12801 East 17th Avenue, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 95:2325-33. 2010
  9. ncbi Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism
    Vibha Sharma
    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, Aurora, CO 80045, USA
    Thyroid 20:1103-11. 2010
  10. ncbi Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
    Joshua P Klopper
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    PPAR Res 2010:729876. 2010

Collaborators

Detail Information

Publications10

  1. ncbi Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, USA
    Mol Cancer 8:16. 2009
    ..Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid x receptor selective agonist, and thiazolidinediones (TZD), PPARgamma selective ligands, as novel treatments...
  2. ncbi Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment
    Joshua P Klopper
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Box B151, 4200 East 9th Avenue, Denver, CO 80262, USA
    Mol Cancer Ther 3:1011-20. 2004
    ..Additionally, expression of both RXRgamma and PPARgamma may be necessary for maximal growth inhibition by ligands and may be required for the increased apoptosis...
  3. ncbi In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma
    Joshua P Klopper
    Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, USA
    Clin Cancer Res 14:589-96. 2008
    ..Additionally, we explore potential mediators of the rexinoid effect on a responsive anaplastic thyroid cancer using comparative microarray analysis...
  4. ncbi Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
    Jena D French
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 97:E934-43. 2012
    ..Novel prognostic markers may be helpful in guiding a therapeutic approach. Our previous studies revealed that immune suppression is evident in PTC and associated with more severe disease...
  5. ncbi Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids
    Bryan R Haugen
    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Clin Endocrinol Metab 89:272-80. 2004
    ..In summary, we identified the RARbeta and RXRgamma isoform to be differentially expressed in thyroid cancer cell lines and tumor tissue. These isoforms seem to predict response to retinoid therapy in thyroid cancer cell lines...
  6. ncbi Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult
    David Howard
    Department of Medicine, Division of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 96:1966-70. 2011
    ..Consumptive hypothyroidism has primarily been described as a paraneoplastic syndrome in infants as well as in two adults with D3-expressing tumors...
  7. ncbi Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification
    Rebecca E Schweppe
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 93:4331-41. 2008
    ..Cell lines derived from human cancers provide critical tools to study disease mechanisms and develop novel therapies. Recent reports indicate that up to 36% of cell lines are cross- contaminated...
  8. ncbi Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer
    Jena D French
    Department of Medicine, University of Colorado Denver, 12801 East 17th Avenue, Aurora, Colorado 80045, USA
    J Clin Endocrinol Metab 95:2325-33. 2010
    ..Immune-based therapies are under investigation to treat many types of cancer. The role of the immune system in PTC is poorly understood...
  9. ncbi Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism
    Vibha Sharma
    Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, Aurora, CO 80045, USA
    Thyroid 20:1103-11. 2010
    ..The objective of this study was to analyze the response to VDR agonist therapy in a panel of validated thyroid cancer cells and assess genetic markers predicting sensitivity and resistance to calcitriol and the noncalcemic analog DP006...
  10. ncbi Combination PPARgamma and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
    Joshua P Klopper
    Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    PPAR Res 2010:729876. 2010
    ..These studies provide insight into potential mechanisms of tumor response or resistance to these novel therapies...